Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.

Abstract

BACKGROUND:

Nephrotic syndrome (NS) is characterized by water and sodium retention, which leads to edema. The non-osmotic stimulation of arginine vasopressin release from the pituitary gland has been implicated as one of the important factors in abnormal water retention in patients with NS.

CASE-DIAGNOSIS/TREATMENT:

We present the initial description of a patient with massive edema caused by refractory nephrotic syndrome, which was effectively treated with tolvaptan, a selective oral vasopressin V2 receptor antagonist.

CONCLUSIONS:

Tolvaptan is effective for the treatment of massive edema caused by NS. Larger studies are needed in the future to fully assess the value and safety of tolvaptan use for this condition.

• Authors: Masaki Shimizu, Sayaka Ishikawa, Yusuke Yachi, Masahiro Muraoka, Yuko Tasaki, Hidenori Iwasaki, Mondo Kuroda, Kazuhide Ohta, Akihiro Yachie
• Journal: Pediatric nephrology (Berlin, Germany) (Pediatr Nephrol) Vol. 29 Issue 5 Pg. 915-7 (May 2014) ISSN: 1432-198X [Electronic] Germany
• PMID: 24240509 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antidiuretic Hormone Receptor Antagonists
• Benzazepines
• Tolvaptan
• Prednisolone

Topics

• Anti-Inflammatory Agents (therapeutic use)
• Antidiuretic Hormone Receptor Antagonists (therapeutic use)
• Benzazepines (therapeutic use)
• Child
• Edema (drug therapy, etiology)
• Female
• Humans
• Nephrotic Syndrome (complications)
• Prednisolone (therapeutic use)
• Renal Dialysis
• Tolvaptan
• Urodynamics